News

Second quarter 2019 revenue of $131 million Second quarter 2019 net loss of $44 million Second quarter 2019 Adjusted EBITDA1 of $60 million Generated cash flow from operating activities of $97 million

ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced...

ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the...

ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or the "Company") (TSX:ADVZ), a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced...

ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced...

Find here our corporate presentation with information relating to etc ...

ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced...

First quarter 2019 revenue of $136 million First quarter 2019 net loss of $8 million First quarter 2019 Adjusted EBITDA1 of $65 million Generated cash flow from operations of $46 million in the...

ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the...

Company acquires international rights to Salagen® tablets (pilocarpine hydrochloride) (excluding Japan rights) and Panretin® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments. ADVANZ PHARMA will pay for the acquisition with cash on hand.

2018 revenue of $537 million, fourth quarter 2018 revenue of $118 million 2018 net income of $1.5 billion, which includes a $1.9 billion gain on debt settlement as part of the Company's...

ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the...

ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), an international specialty pharmaceutical company focused on helping innovate, shape and grow the specialty, off-patent sector in...

Concordia International Corp. ("Concordia" or "the Company") (TSX: CXR), today announced that shareholders voted in favour of a special resolution authorizing the Company to amend its articles to...

Third quarter net income of $1.8 billion, which includes a $1.9 billion gain on debt settlement as part of the Company's recently completed transaction to realign its capital structure (the "Recapitalization Transaction")

Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines,...

Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines,...

International specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that it has appointed pharmaceutical industry expert Frances Cloud to its board of directors. Ms. Cloud's appointment will take effect on November 1, 2018.

The Company intends to rebrand as ADVANZ PHARMA during the fourth quarter of 2018.

The Name Change is subject to approval by Limited Voting Shareholders ("Shareholders") at the Meeting.

As described in the Company's management information circular dated May 15, 2018, and previous press releases issued in connection with the Recapitalization Transaction, the terms of the Recapitalization Transaction and the CBCA Plan, including the terms and US$13.69 issue price of the Private Placement, were extensively negotiated among the Company, holders of its secured debt, holders of its unsecured debt, the participants in the Private Placement, and their respective advisors.

Update on the implementation of Concordia's recapitalization transaction.

Update On Concordia's Recently Completed Recapitalization

Concordia International Corp. Announces Second Quarter 2018 Results

Update on Concordia's Recapitalization Transaction

Concordia Completes Recapitalization Transaction